As of Wednesday close, Incyte Corporation’s (NASDAQ:INCY) stock was down -$0.68, moving down -1.04 percent to $64.73. The average number of shares traded per day over the past five days has been 1,370,800 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.69 fall in that time frame. In the last twenty days, the average volume was 1,501,770, while in the previous 50 days, it was 1,900,402.
Since last month, INCY stock rose 4.94%. Shares of the company fell to $61.03 on 07/18/23, the lowest level in the past month. A 52-week high of $86.29 was reached on 01/26/23 after having rallying from a 52-week low of $60.56. Since the beginning of this year, INCY’s stock price has dropped by -19.41% or -$15.59, and marked a new high 10 times. However, the stock has declined by -24.99% since its 52-week high.
INCY stock investors should be aware that Incyte Corporation (INCY) stock had its last reported insider trading activity 16 days ago on Aug 01. Stein Steven H, the EVP & Chief Medical Officer of the company, disposed of 21,511 shares for $63.28 on Aug 01. It resulted in a $1,361,216 divestment by the insider. Pasquale Maria E sold 802 shares at an average price of $84.06 on Jan 31. The insider now owns 68,524 shares following the transaction. On Jan 30, EVP & General Counsel Pasquale Maria E sold 60,024 shares at $84.74 apiece. The transaction was valued at $5,086,569.
Valuation Metrics
Right now, Incyte Corporation (INCY) has a P/E ratio of about 39.76. The stock’s beta is 0.69. Besides these, the trailing price-to-sales (P/S) ratio of 4.10, the price-to-book (PB) ratio of 3.05, and the price-to-cash flow ratio of 20.22 may also be considered.
Financial Health
In the three months ended June 29, Incyte Corporation’s quick ratio stood at 3.80, while its current ratio was 3.80, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.01, and the total debt-to-equity ratio was 0.01. On the profitability front, the trailing twelve-month gross margin is 93.80% percent. In the year ended June 29, EBITDA margin amounted to 19.66%, whereas operating margins totaled 12.20%. Based on annual data, INCY earned $3.19 billion in gross profit and brought in $3.39 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 8.90%. Return on equity (ROE) for the past 12 months was 8.20%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. INCY’s revenue rose 4.53% to $808.67 million during the quarter, while net income inched up to $954.61 million. While analysts expected Incyte Corporation to report $0.83 quarterly earnings, the actual figure was $0.99 per share, beating the consensus estimate by 19.30%. During the quarter, the company generated $214.08 million in EBITDA. The liabilities of Incyte Corporation were 1.47 billion at the end of its most recent quarter ended June 29, and its total debt was $39.74 million. The value of shareholders’ equity is $224.09 million.
Technical Picture
This quick technical analysis looks at Incyte Corporation’s (INCY) price momentum. With a historical volatility rate of 19.27%, the RSI 9-day stood at 51.79% on 16 August.
With respect to its five-day moving average, the current Incyte Corporation price is down by -1.05% percent or -$0.69. At present, INCY shares trade +2.91% above its 20-day simple moving average and -10.42% percent below its 100-day simple moving average. However, the stock is currently trading approximately +3.78% above its SMA50 and -11.16% below its SMA200.
Stochastic coefficient K was 69.11% and Stochastic coefficient D was 75.67%, while ATR was 1.22. Given the Stochastic reading of 59.74% for the 14-day period, the RSI (14) reading has been calculated as 53.46%. As of today, the MACD Oscillator reading stands at 0.09, while the 14-day reading stands at 0.38.
Analyst Ratings
Citigroup launched its rating on Incyte Corporation (NASDAQ: INCY) to a Buy in a note to investors on July 25, 2023. Incyte Corporation (INCY) has been rated Overweight by analysts. According to 0 brokerage firms, INCY is a sell, and 11 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Incyte Corporation stock as buy, with 9 recommending it as overweight.
With a median target price of $82.00, the current consensus forecast for the stock is $65.00 – $114.00. Based on these forecasts, analysts predict Incyte Corporation (INCY) will achieve an average price target of $82.52.
